[go: up one dir, main page]

ES2194480T3 - Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion. - Google Patents

Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.

Info

Publication number
ES2194480T3
ES2194480T3 ES99931261T ES99931261T ES2194480T3 ES 2194480 T3 ES2194480 T3 ES 2194480T3 ES 99931261 T ES99931261 T ES 99931261T ES 99931261 T ES99931261 T ES 99931261T ES 2194480 T3 ES2194480 T3 ES 2194480T3
Authority
ES
Spain
Prior art keywords
preparation
coating
procedure
oral pharmaceutical
activity compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99931261T
Other languages
English (en)
Inventor
Darder Carlos Picornell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Liconsa SA
Original Assignee
Liconsa Liberacion Controlada de Sustancias Activas SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8304581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2194480(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Liconsa Liberacion Controlada de Sustancias Activas SA filed Critical Liconsa Liberacion Controlada de Sustancias Activas SA
Application granted granted Critical
Publication of ES2194480T3 publication Critical patent/ES2194480T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Comprende un compuesto de actividad antifúngica como principio activo, un núcleo inerte y un recubrimiento que incluye dicho principio activo, y se caracteriza por el hecho de que dicho núcleo inerte presenta un tamaño de partícula comprendido entre 50-600 µm, y por el hecho de que dicho recubrimiento comprende una única capa que se obtiene por nebulización, sobre dicho núcleo inerte, de una solución que comprende un compuesto de actividad antifúngica, un polímero hidrofílico y un agente tensioactivo no iónico. El procedimiento se lleva a cabo mediante un recubrimiento que comprende una única capa de los núcleos inertes de tamaño entre 50 y 600 µm por nebulización de una solución compuesta por el agente antifúngico, el polímero hidrofílico y el agente tensioactivo no iónico a una velocidad de recubrimiento constante durante todo el proceso; y un solo secado de dicho recubrimiento en el mismo equipo.
ES99931261T 1998-07-21 1999-07-20 Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion. Expired - Lifetime ES2194480T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009801539A ES2157731B1 (es) 1998-07-21 1998-07-21 Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.

Publications (1)

Publication Number Publication Date
ES2194480T3 true ES2194480T3 (es) 2003-11-16

Family

ID=8304581

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009801539A Expired - Fee Related ES2157731B1 (es) 1998-07-21 1998-07-21 Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
ES99931261T Expired - Lifetime ES2194480T3 (es) 1998-07-21 1999-07-20 Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES009801539A Expired - Fee Related ES2157731B1 (es) 1998-07-21 1998-07-21 Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.

Country Status (30)

Country Link
US (1) US6737082B1 (es)
EP (1) EP1103252B1 (es)
JP (1) JP4190732B2 (es)
KR (1) KR100572135B1 (es)
AT (1) ATE234077T1 (es)
AU (1) AU750730B2 (es)
BG (1) BG65187B1 (es)
BR (1) BR9912300A (es)
CA (1) CA2337509C (es)
CZ (1) CZ291938B6 (es)
DE (1) DE69905905T2 (es)
DK (1) DK1103252T3 (es)
EE (1) EE04415B1 (es)
ES (2) ES2157731B1 (es)
HR (1) HRP20010128B1 (es)
HU (1) HU228895B1 (es)
IL (1) IL140910A (es)
ME (1) MEP26708A (es)
MX (1) MXPA01000681A (es)
NO (1) NO320054B1 (es)
NZ (1) NZ509886A (es)
PL (1) PL194740B1 (es)
PT (1) PT1103252E (es)
RS (1) RS50063B (es)
RU (1) RU2209628C2 (es)
SK (1) SK283279B6 (es)
TR (1) TR200100177T2 (es)
UA (1) UA64009C2 (es)
WO (1) WO2000004881A1 (es)
ZA (1) ZA200101293B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027764A1 (en) * 1996-01-31 1997-08-07 South Alabama Medical Science Foundation Food and vitamin preparations containing the natural isomer of reduced folates
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
SK8562002A3 (en) 1999-12-23 2003-10-07 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
DK1438961T4 (da) * 2003-01-14 2014-11-17 Acino Pharma Ag Bioækvivalent sammensætning af itraconazol dispergeret i en hydrofil polymer
DE60312635T3 (de) * 2003-01-14 2013-05-08 Cimex Pharma Ag Zusammensetzung in Form eines festen Dispersion enthaltend Itraconazol und ein hydrophilisches Polymer mit einer verbesserten Bioverfügbarkeit
FR2852607B1 (fr) * 2003-03-20 2006-07-14 Procede de fabrication de microspheres de sucre de petite taille, les microspheres susceptibles d'etre obtenues par ce procede et leurs applications
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
DK1648467T3 (en) * 2003-07-17 2018-06-25 Janssen Sciences Ireland Uc PROCEDURE FOR MANUFACTURING PARTICLES CONTAINING AN ANTIVIRUS AGENT
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
CA2619889C (en) 2005-08-22 2020-05-05 The Johns Hopkins University Use of itraconazole and salts thereof for treating cancer
CN101283984B (zh) * 2007-04-12 2010-05-26 永胜药品工业股份有限公司 高生物使用率的经杀真菌剂和聚合物涂覆的核心微粒状物
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2011107466A2 (de) * 2010-03-05 2011-09-09 Basf Se Schmelzüberzogene arzneiformen
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
MX2017015137A (es) * 2015-05-25 2018-03-28 Sun Pharmaceutical Ind Ltd Composicion farmaceutica oral de dosis diaria de isotretinoin.
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
AU2017310506B2 (en) 2016-08-11 2019-11-21 Dmk Pharmaceuticals Corporation Drug compositions
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法
WO2019113493A1 (en) 2017-12-08 2019-06-13 Adamis Pharmaceuticals Corporation Drug compositions
WO2019208801A1 (ja) * 2018-04-27 2019-10-31 凸版印刷株式会社 徐放性複合粒子、徐放性複合粒子の製造方法、乾燥粉体及び壁紙
CA3107214A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
CN118695852A (zh) * 2021-12-22 2024-09-24 帕劳制药有限公司 多颗粒阿巴康唑组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
TW349870B (en) * 1993-09-30 1999-01-11 Janssen Pharmaceutica Nv An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
CN1165291C (zh) * 1996-05-20 2004-09-08 詹森药业有限公司 具有改进的生物利用度的抗真菌组合物
HU221371B1 (en) * 1996-05-24 2002-09-28 Schering Corp Antifungal pharmaceutical composition with enhanced bioavailability
CZ421498A3 (cs) * 1996-06-28 1999-06-16 Schering Corporation Orální prostředek obsahující triazolovou antifungální sloučeninu
DE19626924C2 (de) * 1996-07-04 1999-08-19 Epazon B V Gerät zur Bereitstellung eines Atemgases
JP3608800B2 (ja) 1997-03-26 2005-01-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗真菌剤およびポリマーでコートされたコアを有するペレット剤

Also Published As

Publication number Publication date
SK862001A3 (en) 2001-08-06
CA2337509A1 (en) 2000-02-03
MEP26708A (en) 2010-06-10
CZ291938B6 (cs) 2003-06-18
HUP0103708A2 (hu) 2002-02-28
PL194740B1 (pl) 2007-06-29
IL140910A (en) 2004-03-28
HRP20010128B1 (en) 2003-12-31
DK1103252T3 (da) 2003-07-14
CA2337509C (en) 2005-12-27
DE69905905T2 (de) 2004-03-04
EP1103252A1 (en) 2001-05-30
HK1037531A1 (en) 2002-02-15
PT1103252E (pt) 2003-07-31
ATE234077T1 (de) 2003-03-15
ES2157731A1 (es) 2001-08-16
JP2002521323A (ja) 2002-07-16
ZA200101293B (en) 2001-08-21
AU4782199A (en) 2000-02-14
HU228895B1 (en) 2013-06-28
BR9912300A (pt) 2001-04-17
HRP20010128A2 (en) 2002-12-31
JP4190732B2 (ja) 2008-12-03
IL140910A0 (en) 2002-02-10
SK283279B6 (sk) 2003-05-02
NO20010289D0 (no) 2001-01-17
PL345625A1 (en) 2002-01-02
KR20010070990A (ko) 2001-07-28
AU750730B2 (en) 2002-07-25
NO20010289L (no) 2001-03-07
YU3901A (sh) 2003-08-29
ES2157731B1 (es) 2002-05-01
TR200100177T2 (tr) 2001-07-23
WO2000004881A1 (es) 2000-02-03
KR100572135B1 (ko) 2006-04-19
EE04415B1 (et) 2005-02-15
NO320054B1 (no) 2005-10-17
BG105282A (en) 2001-11-30
NZ509886A (en) 2002-09-27
DE69905905D1 (de) 2003-04-17
RS50063B (sr) 2009-01-22
CZ2001175A3 (en) 2001-05-16
MXPA01000681A (es) 2002-04-24
EP1103252B1 (en) 2003-03-12
US6737082B1 (en) 2004-05-18
EE200100041A (et) 2002-06-17
UA64009C2 (en) 2004-02-16
RU2209628C2 (ru) 2003-08-10
BG65187B1 (bg) 2007-06-29
HUP0103708A3 (en) 2002-07-29

Similar Documents

Publication Publication Date Title
ES2194480T3 (es) Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
CA2396152A1 (en) Osmotic device within an osmotic device
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
CA2446712A1 (en) System for osmotic delivery of pharmaceutically active agents
IS4328A (is) Fjöleininga lyfjablanda sem inniheldur prótónupumpublokkara
ATE334663T1 (de) Arzneimittelzusammensetzung mit verzögerter wirkstoffabgabe
JP2003512395A5 (es)
CA2322875A1 (en) A coated chewing gum, a method for preparation thereof and the use of one or more active substance(s) in solid form
PE20001322A1 (es) Composicion multiparticula de liberacion modificada
ES2052016T3 (es) Composicion emulsionada.
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
ES2190819T3 (es) Procedimiento de preparacion de formulaciones galenicas noveles que contienen fenobrinato, formulaciones galenicas asi obtenidas y sus aplicaciones.
PE3296A1 (es) Composicion oral conteniendo un mucoadhesivo
DK1077680T3 (da) Fremgangsmåde til fremstilling af en med bånd forsynet aktivt-stof-doseringsform til prolongeret release
ES2101082T3 (es) Composiciones de liberacion controlada.
CO5140128A1 (es) Peliculas de poliuretano preparadas a partir de disperciones de poliuretano
CO5251434A1 (es) Composicion de liberacion controlada
EP0113009A3 (de) Antimykotische Mittel mit hoher Wirkstoff-Freisetzung in Form von Gelsystemen
AU1389702A (en) Optically active 2,5-bisaryl-delta<sup>1</sup>-pyrrolines and their use as pest control agents
EP1206907A4 (en) HERBICIDAL COMPOSITIONS AND METHODS OF USE
RU96115480A (ru) Лекарственное средство, обладающее холелитолитическим действием
AR033862A1 (es) Formulacion de medicamento que contiene un agente agonista muscarinico
RU2002133953A (ru) Способ лечения больных генерализованным пародонтитом
RU99118348A (ru) Средство для подавления роста сульфатвосстанавливающих бактерий